Search results for "Pertussi"

showing 10 items of 89 documents

Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults

2000

Abstract To assess the reactogenicity and immunogenicity of the Biken acellular pertussis vaccine (Pa) following administration of a single vaccine dose to young adults with or without a history of prior pertussis immunization, 104 healthy, male and female adults without primary pertussis immunization were enrolled in Mainz (former West Germany; “not previously pertussis vaccinated”, N-PPV-group); in parallel, 103 adults with a history of having received ≥four doses of a combined diphtheria-, tetanus-toxoid, whole-cell pertussis vaccine (DTwP) were enrolled in Magdeburg (former East Germany; “previously pertussis-vaccinated”, PPV-group). Large areas of redness (>20 mm) were seen in 2.9%/1.0…

AdultMaleDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisVaccines AcellularHumansMedicineVirulence Factors BordetellaYoung adultAdhesins BacterialWhooping coughPertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthToxoidAntibody titerToxoidsmedicine.diseaseAntibodies BacterialHemagglutininsInfectious DiseasesImmunologyMolecular MedicinePertussis vaccineFemaleSafetybusinessmedicine.drugVaccine
researchProduct

Cellular Immunity in Adolescents and Adults following Acellular Pertussis Vaccine Administration

2007

ABSTRACT Cell-mediated immune (CMI) responses to an acellular pertussis vaccine administered to 49 subjects, a subset of participants in the National Institutes of Health-funded adult acellular pertussis vaccine efficacy trial, were evaluated and compared with antibody responses to vaccine antigens. Levels of proliferation of and cytokine secretion from lymphocytes cultured in the presence of pertussis toxin, filamentous hemagglutinin, or pertactin were measured before vaccination and 1 month and 1 year after vaccination. Statistically significant increases in lymphocyte stimulation indices and cytokine secretion were noted at both 1 month and 1 year after vaccination. Brisk pertussis antig…

AdultMaleMicrobiology (medical)Cellular immunityBordetella pertussisAdolescentClinical BiochemistryImmunologyLymphocyte ActivationPertussis toxincomplex mixturesBordetella pertussisInterferon-gammaVaccines AcellularHumansImmunology and AllergyMedicinePertussis Vaccinebiologybusiness.industryVaccinationMiddle AgedVaccine ResearchVaccine efficacybiology.organism_classificationAntibodies BacterialVaccinationImmunologyPertussis vaccineFemaleCytokine secretionPertactinbusinessmedicine.drugClinical and Vaccine Immunology
researchProduct

Symptoms and complications of pertussis in adults

1995

There is increasing evidence that pertussis occurs frequently in adults, but there is limited information on the clinical course of this disease beyond childhood. A household contact study on the efficacy of an acellular pertussis vaccine was used to study the symptoms of pertussis in adults. Among 257 patients with pertussis identified in 121 families during a two-year period in one study center with a low whole-cell pertussis-vaccine uptake, 79 (30.7%) were adults, aged 19–83 years (mean age: 36 years) with a 1:1.8 male to female ratio. Ninety-one percent of the adults suffered from coughing (mean duration: 54 days), and in 80% this cough lasted ≥ 21 days. Whoops were rare (8%), whereas c…

AdultMaleSleep Wake DisordersMicrobiology (medical)Pediatricsmedicine.medical_specialtyVomitingWhooping CoughPainPoison controlEnzyme-Linked Immunosorbent AssaySweatingSneezingBordetella pertussisNasopharynxmedicineHumansProspective StudiesChildProspective cohort studyWhooping coughAgedAged 80 and overPertussis VaccineHoarsenessbusiness.industryHeadacheGeneral MedicineMiddle Agedmedicine.diseaseAntibodies BacterialAirway ObstructionInfectious DiseasesCoughAnesthesiaVomitingPertussis vaccineFemaleHeadachesmedicine.symptomChokingComplicationbusinessmedicine.drugInfection
researchProduct

How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy.

2005

Abstract The epidemiology of pertussis in Italy is described by using data from the statutory notification system and from seroepidemiology studies. Starting from the 1990s, the incidence of pertussis in Italy has shown a sharp decline and is now at the lowest level ever reached. During this time period vaccination coverage has increased from 88% in 1998 to 95% in 2003. In 1996–97, the prevalence of subjects with levels of IgG antibodies against PT greater than 2 EU/ml was 77.6%. The increase in vaccination coverage will probably change the pattern of disease transmission and increase the number of susceptible adults, unless administration of booster doses to adolescents and adults is consi…

AdultMalemedicine.medical_specialtyPediatricsAdolescentWhooping CoughImmunization SecondaryMandatory ProgramsMass VaccinationPertussiSeroepidemiologic StudiesEpidemiologyMedicineHumansPertussis vaccinationRegistriesChildWhooping coughSeroepidemiologyVaccination coveragePertussis VaccineBooster (rocketry)General VeterinaryGeneral Immunology and Microbiologybusiness.industryIncidence (epidemiology)Public Health Environmental and Occupational HealthAge FactorsInfantmedicine.diseaseAntibodies BacterialInfectious DiseasesItalyVaccination coverageChild PreschoolPopulation SurveillanceImmunologyMolecular MedicineFemalebusinessTos ferinaDisease transmissionVaccine
researchProduct

Whooping cough, twenty years from acellular vaccines introduction

2015

Clinical pertussis resulting from infection with B. pertussis is a significant medical and public health problem, despite the huge success of vaccination that has greatly reduced its incidence. The whole cell vaccine had an undeniable success over the last 50 years, but its acceptance was strongly inhibited by fear, only partially justified, of severe side effects, but also, in the Western world, by the difficulty to enter in combination with other vaccines: today multi-vaccine formulations are essential to maintain a high vaccination coverage. The advent of acellular vaccines was greeted with enthusiasm by the public health world: in the Nineties, several controlled vaccine trials were car…

AdultPertussis VaccineAcellular vaccinesSecondaryVaccinesSettore MED/07 - Microbiologia E Microbiologia ClinicaTime FactorsAdolescentWhooping CoughMedicine (all)VaccinationImmunization SecondaryVaccine trialInfantVaccines AcellularImmunoprotectionPertussiPertussisAcellularItalyHumansAcellular vaccines; Immunoprotection; Pertussis; Vaccine trials; Adolescent; Adult; Humans; Immunization Secondary; Infant; Italy; Pertussis Vaccine; Time Factors; Vaccination; Vaccines Acellular; Whooping CoughImmunizationVaccine trialsAcellular vaccine
researchProduct

Experts’ Opinion for Improving Pertussis Vaccination Rates in Adolescents and Adults: A Call to Action

2022

This article highlights the importance of diphtheria-tetanus-acellular pertussis (with reduced antigen content, dTap) vaccination in preventing pertussis, a respiratory infection that is still widespread and easily transmitted. In particular, it highlights the need to receive a booster vaccination throughout life to maintain high antibody levels, which decrease through time. This document collects the opinions that emerged from the comparison between major Italian experts in the field of vaccination. This working group was created to promote a “call to action”, aimed at raising awareness among all institutions, public health authorities, and health workers involved in the vaccination proces…

AdultTetanuspertussis vaccineAdolescentWhooping CoughHealth Toxicology and MutagenesisVaccinationpertussis vaccine in pregnancy.Public Health Environmental and Occupational Healthpertussis booster for adultDiphtheriapertussis immunity durationDiphtheria-Tetanus-acellular Pertussis VaccinesAntibodies Bacterialpertussis immunizationdTap vaccinePregnancypertussiHumansFemaleDiphtheria-Tetanus-Pertussis VaccineInternational Journal of Environmental Research and Public Health
researchProduct

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model

2003

The reduced antigen content diphtheria, tetanus and pertussis (dTpa) vaccine (Boostrixtrade mark) has been shown to induce a strong booster response to all the vaccine components in 4-6 year olds. However, anti-diphtheria antibody levels were observed to be lower when compared to the "full strength" paediatric DTPa vaccine. To assess the impact of this difference on long-term protection, a mathematical model was developed to predict diphtheria antibody decay over time. The model was based on a linear decrease in log-transformed antibody concentrations after the first year post-vaccination. When applied to data collected 3.5 years after vaccination of 4-6 year olds with either DTPa or dTpa, …

AdultTime Factorsanimal diseasesImmunization SecondaryModels Biologicalcomplex mixturesCohort StudiesAntigenmedicineHumansChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleRandomized Controlled Trials as TopicBooster (rocketry)General VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaVaccinationPublic Health Environmental and Occupational HealthDiphtheriarespiratory systemmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationChild PreschoolImmunologycardiovascular systembiology.proteinMolecular MedicineAntibodybusinessDiphtheria antibodycirculatory and respiratory physiologyVaccine
researchProduct

Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell pro…

2013

Abstract The beta3 adrenergic receptor (B3-AR) reportedly induces cell proliferation, but the signaling pathways that were proposed, involving either Gs or Gi coupling, remain controversial. To further investigate the role of G protein coupling in B3-AR induced proliferation, we stimulated primary human myometrial smooth muscle cells with SAR150640 (B3-AR agonist) in the absence or presence of variable G-protein inhibitors. Specific B3-AR stimulation led to an Erk1/2 induced proliferation. We observed that the proliferative effects of B3-AR require two Erk1/2 activation peaks (the first after 3 min, the second at 8 h). Erk1/2 activation at 3 min was mimicked by forskolin (adenylyl-cyclase a…

Beta-3 adrenergic receptorGs alpha subunitMAP Kinase Signaling SystemMyocytes Smooth MuscleProliferationG protein coupled receptorBiologyGTP-Binding Protein alpha Subunits Gi-GoPertussis toxinchemistry.chemical_compoundErk1/2Protein kinasesCyclinsReceptors Adrenergic betaGTP-Binding Protein alpha Subunits GsHumansMolecular BiologyPI3K/AKT/mTOR pathwayCells CulturedG protein-coupled receptorCell ProliferationForskolinColforsinBeta-3 adrenergic receptorCell BiologyCell biologychemistryGene Expression RegulationPertussis ToxinMyometriumFemaleSignal transductionProto-oncogene tyrosine-protein kinase SrcBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

1996

The aim of this study was to investigate pertussis-specific cell-mediated immunity in infants vaccinated with a tricomponent acellular vaccine. Infants were investigated during a primary vaccination schedule from the third month of life to the sixth month as well as before and after a booster at 15 to 24 months. This is the first report of specific cell-mediated immune responses to pertussis-related antigens in infants below the age of 12 months. Our data show that the vaccine induces T-cell responses specific for the vaccine components, detoxified pertussis toxin, filamentous hemagglutinin, and pertactin, that increase progressively over the course of the vaccination schedule. In contrast …

Bordetella pertussisCellular immunityVaccination scheduleT-LymphocytesImmunologyLymphocyte ActivationMicrobiologyBordetella pertussisImmunophenotypingImmune systemImmunityHumansVirulence Factors BordetellaAntigens BacterialbiologyVaccinationInfantbiology.organism_classificationVirologyAntibodies BacterialVaccinationInfectious DiseasesPertussis ToxinImmunologyCytokinesParasitologyCytokine secretionPertactinResearch Article
researchProduct

Characterization of the Purified Fourth Component of Guinea Pig Complement* *Supported by Deutsche Forschungsgemeinschaft (grant Kl 124/9).

1970

Publisher Summary A strain of rabbits deficient in complement was discovered in Freiburg, Germany in 1961. A second, clearly unrelated, strain was reported in Mexico. Both these strains are deficient in C6. A further complement-deficient rabbit was found by chance in Cambridge. This paper presents some data on the colony bred from this animal. C6 was partially purified from rabbit serum by chromatography on DEAE Cellulose and hydroxyapatite. Antibody to rabbit C6 in deficient rabbits was raised by four weekly injections of alum precipitated C6 with Bordetella pertussis as adjuvant into the knee joints, followed by three intravenous injections of the alum precipitated material without B. per…

Bordetella pertussisLysisbiologyChemistryAlummedicine.medical_treatmentC5 Deficiencybiology.organism_classificationmedicine.diseaseHemolysisMicrobiologyGuinea pigchemistry.chemical_compoundBiochemistrybiology.proteinmedicineAntibodyAdjuvant
researchProduct